HSNOHbio is a New York-based biotechnology venture dedicated to discovering innovative treatments for central nervous system disorders.
Founded with a vision to integrate artificial intelligence, molecular engineering, and neuroscience, HSNOHbio focuses on developing novel therapeutic candidates targeting important neurological mechanisms.
Our primary research program investigates GluA3-selective allosteric modulation of AMPA receptors, a potential approach to developing more targeted CNS therapeutics.
Our lead candidate, G3-01EG, was designed through computational molecular modeling and structure-guided drug discovery.
HSNOHbio follows a milestone-driven development approach:
AI-assisted molecular discovery
Structure-based compound optimization
Selective receptor binding validation
Electrophysiological functional characterization
Preclinical pharmacology and safety evaluation
Strategic partnerships for clinical development
To become an innovative biotechnology company advancing precision neurotherapeutics through scientific discovery and global collaboration.
Founder & CEO | HSNOHbio
Independent CNS Drug Discovery Researcher & Chemical Industry Professional
Hyunsub Noh is the Founder and CEO of HSNOHbio, a U.S.-based biotechnology venture pioneering computational approaches to the discovery of therapeutics for central nervous system (CNS) disorders.
With approximately two decades of professional experience in South Korea's chemical industry, additional experience in American chemical companies, and an interdisciplinary foundation in polymer engineering, biotechnology, and independent neuroscience research, he brings a distinctive combination of scientific knowledge, industrial experience, and entrepreneurial vision to early-stage drug discovery.
He earned his Bachelor's degree in Polymer Engineering from Dankook University, South Korea, and subsequently pursued biotechnology coursework at Hudson Valley Community College in New York.
Driven by a longstanding interest in human health and neurological disorders, he expanded his scientific knowledge through independent studies in neurobiology, molecular pharmacology, receptor biology, and computational drug design.
His career includes approximately 20 years in South Korea's chemical industry, where he gained extensive experience in chemical products, industrial materials, sales, commercial operations, and business development.
He also worked at the National Cancer Center, Korea, supporting patient convenience facilities through retail operations, inventory management, and merchandise coordination. This experience provided firsthand exposure to the operational environment of a major national cancer care institution.
In the United States, he further developed his industrial experience through positions at Surpass Chemical and YINCAE Advanced Materials, gaining practical exposure to chemical material handling and advanced materials operations.
Together, these experiences shaped his multidisciplinary perspective on chemical science, industrial applications, healthcare environments, and biotechnology entrepreneurship.
In 2025, he founded HSNOHbio to pursue the discovery of innovative CNS therapeutics through computational molecular design and structure-based research.
His current research centers on GluA3-selective allosteric modulation of AMPA receptors, an emerging approach to investigating potential therapeutic strategies for neurological and psychiatric disorders.
Under his leadership, HSNOHbio has developed a computationally designed portfolio of candidate molecules, including G3-01EG, a proposed GluA3-selective positive allosteric modulator.
In August 2026, he filed a U.S. provisional patent application related to the company's GluA3 drug discovery platform.
The program is advancing toward experimental proof of concept, including chemical synthesis, receptor-binding selectivity studies, electrophysiological characterization, and subsequent preclinical evaluation.
To transform scientific insight into therapeutic innovation by integrating decades of chemical industry experience, computational molecular design, and collaborative experimental research.
Through HSNOHbio, he aims to establish a research-driven biotechnology enterprise dedicated to exploring new therapeutic possibilities for patients affected by complex CNS disorders.